Mr. Scott is co-founder and CEO of TEGA Therapeutics, a glycobiology company focused on lysosomal storage disorder and recombinant heparan sulfates.  He previously was founder and President of Pharmatek Laboratories, a contract development and manufacturing company (sold to Catalent Pharma Solutions in 2016).  Prior to that, he was Senior Vice President at Active.com (IPO 2011).  Mr. Scott serves on the Board of Avelas, a bioscience company working to create better outcomes for cancer patients with its activatable cell-penetrating peptide technology.  He previously served on the board of Zacharon Pharmaceuticals (sold to Biomarin 2014).  Mr. Scott is a member of the boards of BIOCOM, a non-profit organization supporting the needs of bio/pharma companies in California and CONNECT, a non-profit helping to create and scale innovation companies in San Diego. At UC San Diego, he serves on the Dean's Advisory Council for the Division of Biological Sciences.  In the community, Mr. Scott serves on the board of the San Diego Blood Bank, and as a trustee for the La Jolla Playhouse, a Tony-award winning regional theatre. Mr. Scott earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.

Dr. Glass is co-founder of TEGA Therapeutics, Inc. and serves as President and CSO. Early in his industry career, Dr. Glass led research in various phases of drug-target-gene discovery at RW Johnson, PRI. He recognized that the intense competition for novel drug targets was a fundamental challenge in the pharmaceutical industry. In response, Dr. Glass co-founded Zacharon Pharmaceuticals, Inc., in 2004 to target glycans, which are extremely underrepresented as therapeutic targets. As President of Zacharon, Dr. Glass raised the initial funding for the company through federal grants, angel investors and a round of venture capital financing, later serving as Senior Vice President of Research and as a member of the Board of Directors under the venture firm management. In 2013, Zacharon Pharmaceuticals became part of a larger biotechnology company in a successful merger/acquisition. Dr. Glass earned his B.S. in Biochemistry from the University of Illinois. He earned his Ph.D. in Zoology from the University of California, Berkeley and completed his postdoctoral Fellowship in Molecular Genetics at the University of Chicago.

Dr. Esko is co-founder and Chief Scientific Advisor, Biology of TEGA Therapeutics, Inc. Dr. Esko is also a Professor in the Department of Cellular and Molecular Medicine at the University of California, San Diego. Dr. Esko runs a leading glycobiology lab, is well published, has co-authored the leading textbook on Glycobiology, holds several patents, and is extremely active in the University and community at large. With technology originating in his lab, Dr. Esko co-founded Zacharon Pharmaceuticals, Inc. which went on to develop and expand the technology to new areas ultimately leading to successful merger/acquisition of the company with BioMarin Pharmaceuticals, Inc. Prior to the merger/acquisition, Dr. Esko served as Scientific Advisor and Board member to Zacharon Pharmaceuticals, Inc. He earned his B.S. in Biochemistry from the University of Illinois. He earned his Ph.D. in Biochemistry from the University of Wisconsin and completed his postdoctoral Fellowship in Molecular Biology at University of California, Los Angeles.

Dr. Tor is co-founder and Chief Scientific Advisor, Chemistry of TEGA Therapeutics, Inc. Dr. Tor is also a Professor in the Department of Chemistry and Biochemistry at the University of California, San Diego. 

Dr. Tor's research includes chemistry and biology of nucleosides, nucleotides and nucleic acids, the discovery of novel antiviral and antibacterial agents, as well as the development of cellular delivery agents and biomolecular fluorescent probes. He also serves as the Editor in Chief of Perspectives in Medicinal Chemistry and Organic Chemistry Insights. Dr. Tor is the original inventor of guanidinoglycosides. Dr. Tor earned his Ph.D. at the Weizmann Institute of Science and completed his postdoctoral Fellowship at the California Institute of Technology.

Dr. Brown is Director of Research and Development at TEGA Therapeutics. As the Director, she leads the MPS Program developing enzyme replacement therapies for the treatment of lysosomal storage disorders. Previously, she was a Senior Scientist at BioMarin Pharmaceuticals Inc. and the Biology leader of a small molecule drug discovery program. Prior to that, she was a Group leader at Zacharon Pharmaceuticals Inc.  She is an inventor on several patents filed covering intellectual property in the area of Glycobiology research and the Principal Investigator on several NIH funded grants. Dr. Brown earned her B.S in Chemistry from the University of Dundee, Scotland. She earned her Ph.D. in Biological Chemistry from the University of Dundee and University of St Andrews, Scotland. She completed her postdoctoral studies in Biomedical Sciences at the Glycobiology Research and Training Center at the University of California, San Diego.

Dr. Spliid is a Scientist at TEGA Therapeutics where she leads the development of recombinant glycosaminoglycans for research and therapeutic purposes. She earned an MS and PhD in biochemistry at the University of Copenhagen, Denmark and subsequently did a postdoc at the Glycobiology Research and Training Center at the University of California, San Diego. Her academic research focused on the biosynthesis and biochemical/physiological properties of glycosaminoglycans.